1. Home
  2. OBIO vs FHTX Comparison

OBIO vs FHTX Comparison

Compare OBIO & FHTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • OBIO
  • FHTX
  • Stock Information
  • Founded
  • OBIO 2017
  • FHTX 2015
  • Country
  • OBIO United States
  • FHTX United States
  • Employees
  • OBIO N/A
  • FHTX N/A
  • Industry
  • OBIO Medicinal Chemicals and Botanical Products
  • FHTX Medicinal Chemicals and Botanical Products
  • Sector
  • OBIO Health Care
  • FHTX Health Care
  • Exchange
  • OBIO Nasdaq
  • FHTX Nasdaq
  • Market Cap
  • OBIO 291.7M
  • FHTX 310.9M
  • IPO Year
  • OBIO N/A
  • FHTX 2020
  • Fundamental
  • Price
  • OBIO $8.03
  • FHTX $5.90
  • Analyst Decision
  • OBIO Strong Buy
  • FHTX Buy
  • Analyst Count
  • OBIO 2
  • FHTX 3
  • Target Price
  • OBIO $17.00
  • FHTX $13.00
  • AVG Volume (30 Days)
  • OBIO 249.9K
  • FHTX 145.9K
  • Earning Date
  • OBIO 08-08-2024
  • FHTX 08-02-2024
  • Dividend Yield
  • OBIO N/A
  • FHTX N/A
  • EPS Growth
  • OBIO N/A
  • FHTX N/A
  • EPS
  • OBIO N/A
  • FHTX N/A
  • Revenue
  • OBIO $2,216,000.00
  • FHTX $33,896,000.00
  • Revenue This Year
  • OBIO $17.90
  • FHTX N/A
  • Revenue Next Year
  • OBIO $10.51
  • FHTX $8.63
  • P/E Ratio
  • OBIO N/A
  • FHTX N/A
  • Revenue Growth
  • OBIO N/A
  • FHTX 64.41
  • 52 Week Low
  • OBIO $4.22
  • FHTX $2.70
  • 52 Week High
  • OBIO $11.69
  • FHTX $9.97
  • Technical
  • Relative Strength Index (RSI)
  • OBIO 54.75
  • FHTX 51.91
  • Support Level
  • OBIO $7.80
  • FHTX $5.62
  • Resistance Level
  • OBIO $8.87
  • FHTX $6.98
  • Average True Range (ATR)
  • OBIO 0.60
  • FHTX 0.58
  • MACD
  • OBIO -0.01
  • FHTX 0.09
  • Stochastic Oscillator
  • OBIO 59.02
  • FHTX 51.13

About OBIO Orchestra BioMed Holdings Inc.

Orchestra BioMed Holdings Inc is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships. Its partnership-enabled business model focuses on forging strategic collaborations with medical device companies to drive the global commercialization of the products it develops. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension and Virtue Sirolimus AngioInfusionBalloon (SAB) for the treatment of atherosclerotic artery disease.

About FHTX Foghorn Therapeutics Inc.

Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.

Share on Social Networks: